Retinoprotective Therapy Possibilities: A Cases Series

The article presents a cases series of retinoprotective therapy (RPT) using the water-soluble retinal polypeptide fractions (RPF). The 1st case: the nonproliferative diabetic retinopathy (DR) and cystoid macular edema patient after the 1st year of anti-VEGF therapy and retinal laser coagulation (RLС), which resulted in foveal retinal edema relief, a decrease in its intensity in the paraand perifovea, an increase of the best-corrected visual acuity (BCVA) from 0.03 up to 0.2, and the perimetric indices deviations (MD -12.86 dB; PSD 7.99 dB) relative to normal values. Three courses of RPT were administrated during the 2nd year of anti-VEGF therapy. BCVA increase (up to 0.3), MD normalization (-1.65 dB) and PSD decrease (4.96 dB) were noted 1month after the 3rd course of RPT. The 2nd case: the proliferative DR patient after subtotal 25-G vitrectomy, endo-RLC and silicone oil (SO) tamponade. MD (-8.04 dB) and PSD (4.61 dB) deviations were recorded 1-month after surgery. BCVA stabilization (0.3), MD improvement (-5.43 dB), PSD stabilization (4.61 dB) were noted 1-month after RPT. The 3rd case: the patient with low BCVA (0.08), MD (-14.15 dB) and PSD (7.86 dB) deviations 1-month after vitreous cavity revision with perfluorocarbon (PF) tamponade, endo-RLC and PF replacement with SO due to recurrent retinal detachment after the indirect non-open glob blunt injury. BCVA improved (0.2), MD decreased (-9.38 dB), and PSD stabilized (7.54 dB) one month after RPT. All patients noted improved quality of vision after RPT. The presented clinical cases, as well as many years of experience with the effective and safe use of RPF in patients with retinal pathology, provide grounds for recommending RPT after RLC and vitrectomy in patients with DR and retinal detachment.

1. Kurysheva NI, Korneeva AV, Ponomareva SI. Current Opportunities and Future Prospects of Neuroprotective Therapy in Glaucoma. Literature Review. Part 1. Ophthalmology In Russia. 2025;22(1):5–15 (In Russ.). doi: 10.18008/1816-5095-2025-1-5-15.

2. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discovery Today. 2015;20(1):122–128. doi: 10.1016/j.drudis.2014.10.003.

3. Lau JL, Dunn MK. Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorganic & Medicinal Chemistry. 2018;26:2700–2707. doi: 10.1016/j.bmc.2017.06.052.

4. Apostolopoulos V, Bojarska J, Chai TT. A Global Review on Short Peptides: Frontiers and Perspectives. Molecules. 2021;26(2):430. doi: 10.3390/molecules26020430.

5. Verilov NA, Dorotenko AR, Gulina LS. Study of ligand-receptor interaction and biodistribution under various modes of administration of a medicine containing polypeptides from the livestock eyes retina. The Russian Annals of Ophthalmology. 2021:137(5):88–95 (In Russ.). doi: 10.17116/oftalma202113705188.

6. Chandarana C, Juwarwala I, Shetty S. Peptide Drugs: Current Status and it’s Applications in the Treatment of Various Diseases. Curr Drug Res Rev. 2024;16(3):381– 394. doi: 10.2174/0125899775295960240406073630.

7. Xiao W, Jiang W, Chen Z. Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines. Signal Transduct Target Ther. 2025;10(1):74. doi: 10.1038/s41392-024-02107-5.

8. Omidian H, Cubeddu LX, Wilson RL. Peptide-Functionalized Nanomedicine: Advancements in Drug Delivery, Diagnostics, and Biomedical Applications. Molecules. 2025;30(7):1572. doi: 10.3390/molecules30071572.

9. Danilichev VF, Maximov IB. Eye injuries and diseases: the use of enzymes and peptide bioregulators. Minsk: Science and Technology;1994. 223 p. (In Russ.).

10. Khavinson VKh, Zemchikhina VN, Trofimova SV. Peptide influence on the cell and pigment epithelium proliferative activity. Bulletin of experimental biology and medicine. 2003;135(6):700–702 (In Russ.).

11. Saidasheva EI. Use of Retinalamin for diabetic retinopathy. Pharmateka. 2008: 157(3):52–54 (In Russ.).

12. Egorov EA, Oganezova ZhG, Egorova TE. Possibilities of Retinalamin usage in treatment of dystrophic eye diseases (literary review). RMJ. Clinical Ophthalmology. 2009:10(2):57–58 (In Russ.).

13. Milenkaya TN, Ishenko IM. Retinalamin in patients with diabetic retinopathy. Effective pharmacotherapy in endocrinology. 2009:6:18–22 (In Russ.).

14. Malysheva NA, Rossokhin VF. Use of Retinalaminat early stage of treatment of nonproliferative diabetic retinopathy in children with type 1 diabetes mellitus. Modern Technologies in Medicine. 2011:3:160–162 (In Russ.).

15. Khavinson VKh, Kuznik BI, Ryzhak GA. Peptide bioregulators: the new class of geroprotectors. Message 1. Experimental studies results. Advances in gerontology. 2012;25(4):696–708 (In Russ.).

16. Aznabaev BN, Gabdrahmanova AF, Muhamadeev TR. Ophthalmoneuroprotection in nonproliferative diabetic retinopathy and eye hemodynamics. RMJ. Clinical ophthalmology. 2014:15(2):71 (In Russ.).

17. Razumovskiy MI, Pavlyuchenko KM, Razumovskaya AM. Long-term outcomes of retinal degenerative disorder treatment with peptide bioregulators. Ophthalmology In Russia. 2025;12(2):43–47 (In Russ.). doi: 10.18008/1816-5095-2015-2-43-47.

18. Astakhov YuS, Belova TV, Boiko EV. Efficacy of retinalamin in the complex treatment of rhegmatogenous retinal detachment. Ophthalmology Journal. 2026;9(4): 69–77 (In Russ.). doi: 10.17816/OV9469-77.

19. Neroev VV, Zaitseva OV, Okhotsimskaya TD. The Effectiveness of Retinalamin® Administered by Various Intramuscular Injection Timings in the Treatment of Patients with the Dry Form of Age-Related Macular Degeneration. Russian Ophthalmological Journal. 2016;1:39–46 (In Russ.).

20. Antonov AA, Makarova AS, Reshchikova VS. Experimental studies of Retinalamin efficacy. Russian National Glaucoma Journal. 2017;16(3):98–102 (In Russ.).

21. Egorov EA. Retinalamin for various ophthalmic disorders: clinical experience. RMJ. Clinical ophthalmology. 2017:1:35–38 (In Russ.).

22. Erichev VP, Petrov SYu, Volzhanin AV. Efficiency of retinoprotective dry AMD therapy with Retinalamin®: a randomized clinical trials metanalysis based on the dynamics of visual acuity. RMJ. Clinical ophthalmology. 2017;4:219–226 (In Russ.).

23. Plashevoy VV. Study of the properties of retinalamin in diabetic retinopathy in patients with diabetes mellitus. Trends in the development of science and education. 2020:12:66–68 (In Russ.). doi: 10.18411/lj-12-2020-69.

24. Verilov NA, Dorotenko AR, Gulina LS. Study of ligand-receptor interaction and biodistribution under various modes of administration of a medicine containing polypeptides from the livestock eyes retina. The Russian Annals of Ophthalmology. 2021:137(5):88–95 (In Russ.). doi: 10.17116/oftalma202113705188.

25. Malishev AV, Yanchenko SV, Saverskaya EN. Diabetic Retinopathy: Possibilities and Prospects for Retinoprotection. Ophthalmology In Russia. 2024;21(2):256–263 (In Russ.). doi: 10.18008/1816509520242256263.

26. Parravano M, Cennamo G, Di Antonio L. Multimodal imaging in diabetic retinopathy and macular edema: An update about biomarkers. Surv Ophthalmol. 2024 NovDec;69(6):893–904. doi: 10.1016/j.survophthal.2024.06.006.

27. Madheswaran G, Nasim P, Ballae Ganeshrao S. Role of microperimetry in evaluating disease progression in age-related macular degeneration: a scoping review. Int Ophthalmol. 2022;42(6):1975–1986. doi: 10.1007/s10792-021-02170-9.

28. Sabeti F, van Kleef JP, Iyer RM. Discriminating early-stage diabetic retinopathy with subjective and objective perimetry. Front. Endocrinol. 2024;14:1333826. doi: 10.3389/fendo.2023.1333826.

29. Fayzrakhmanov RR, Sukhanova AV, Pavlovsky OA. The Role of OCT Angiog raphy in a Study of Retinal Perfusion After Endovitreal Intervention Due to Rhegmatogenous Retinal Detachment. Journal of Clinical Practice. 2020;11(3):61–67 (In Russ.). doi: 10.17816/clinpract33960.

30. Yablokov MM, Fabrikantov OL, Yablokova NV. Silicone oil tamponade in surgical treatment of rhegmatogenous retinal detachment. Russian ophthalmological journal. 2022;15(4):173–177 (In Russ.). doi: 10.21516/2072-0076-2022-15-4173-177.